Literature DB >> 10976101

Induction of connective tissue growth factor by activation of heptahelical receptors. Modulation by Rho proteins and the actin cytoskeleton.

A Hahn1, J Heusinger-Ribeiro, T Lanz, S Zenkel, M Goppelt-Struebe.   

Abstract

Expression of connective tissue growth factor (CTGF) was induced in renal mesangial cells by activation of heptahelical receptors by serotonin (5-HT) and lysophosphatidic acid (LPA). Induction of CTGF mRNA was transient with maximal expression after 1 to 2 h, whereas induction of CTGF by transforming growth factor beta (TGF-beta) increased over time. In contrast to the induction of other early response genes (Egr-1 and cyclooxygenase-2), LPA-mediated induction of CTGF was pertussis toxin-insensitive and independent of p42/44 MAP kinase activation. 5-HT-mediated CTGF induction was due to activation of 5-HT(2A) receptors and likewise independent of p42/44 MAP kinase activation. Upon stimulation, enhanced levels of CTGF protein were detected in cellular homogenates, whereas no protein was detectable in cell culture supernatants. Inhibition of proteins of the Rho family by toxin B abrogated basal as well as CTGF expression stimulated by LPA, 5-HT, and TGF-beta. Inhibition of the downstream mediator of RhoA, the Rho kinase by Y-27632 partially reduced induction of CTGF by LPA and TGF-beta. Toxin B not only affected gene expression, but disrupted the actin cytoskeleton similarly as observed after treatment with cytochalasin D. Disassembly of actin stress fibers by cytochalasin D partially reduced basal and stimulated CTGF expression. These data indicate that an intact actin cytoskeleton is critical for the expression of CTGF. Elimination of the input of Rho proteins by toxin B, however, was significantly more effective and their effect on CTGF expression thus goes beyond disruption of the cytoskeleton. These findings thus establish activation of heptahelical receptors coupled to pertussis toxin-insensitive G proteins as a novel signaling pathway to induce CTGF. Proteins of the Rho family and an intact cytoskeleton were identified as critical determinants of CTGF expression induced by LPA and 5-HT, and also by TGF-beta.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10976101     DOI: 10.1074/jbc.M000976200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  26 in total

1.  Serotonin mechanisms in heart valve disease II: the 5-HT2 receptor and its signaling pathway in aortic valve interstitial cells.

Authors:  Jie Xu; Bo Jian; Richard Chu; Zhibin Lu; Quanyi Li; John Dunlop; Sharon Rosenzweig-Lipson; Paul McGonigle; Robert J Levy; Bruce Liang
Journal:  Am J Pathol       Date:  2002-12       Impact factor: 4.307

Review 2.  The role of connective tissue growth factor (CTGF/CCN2) in skeletogenesis.

Authors:  John A Arnott; Alex G Lambi; Christina Mundy; Honey Hendesi; Robin A Pixley; Thomas A Owen; Fayez F Safadi; Steven N Popoff
Journal:  Crit Rev Eukaryot Gene Expr       Date:  2011       Impact factor: 1.807

3.  SHP-2 acts via ROCK to regulate the cardiac actin cytoskeleton.

Authors:  Yvette Langdon; Panna Tandon; Erika Paden; Jennifer Duddy; Joan M Taylor; Frank L Conlon
Journal:  Development       Date:  2012-01-25       Impact factor: 6.868

4.  Role of Rac and Cdc42 in lysophosphatidic acid-mediated cyclo-oxygenase-2 gene expression.

Authors:  Angelika Hahn; Holger Barth; Michaela Kress; Peter R Mertens; Margarete Goppelt-Struebe
Journal:  Biochem J       Date:  2002-02-15       Impact factor: 3.857

5.  A role for serotonin (5-HT) in hepatic stellate cell function and liver fibrosis.

Authors:  Richard G Ruddell; Fiona Oakley; Ziafat Hussain; Irene Yeung; Lesley J Bryan-Lluka; Grant A Ramm; Derek A Mann
Journal:  Am J Pathol       Date:  2006-09       Impact factor: 4.307

6.  Effects of phased joint intervention on Rho/ROCK expression levels in patients with portal hypertension.

Authors:  Min Shi; Jue Wei; Wen-Ying Meng; Na Wang; Ting Wang; Yu-Gang Wang
Journal:  Exp Ther Med       Date:  2016-06-14       Impact factor: 2.447

Review 7.  Lysophosphatidic acid and renal fibrosis.

Authors:  Jean-Philippe Pradère; Julien Gonzalez; Julie Klein; Philippe Valet; Sandra Grès; David Salant; Jean-Loup Bascands; Jean-Sébastien Saulnier-Blache; Joost P Schanstra
Journal:  Biochim Biophys Acta       Date:  2008-04-11

Review 8.  Aiming drug discovery at lysophosphatidic acid targets.

Authors:  Gabor Tigyi
Journal:  Br J Pharmacol       Date:  2010-09       Impact factor: 8.739

9.  Cell permeant peptide analogues of the small heat shock protein, HSP20, reduce TGF-beta1-induced CTGF expression in keloid fibroblasts.

Authors:  Luciana B Lopes; Elizabeth J Furnish; Padmini Komalavilas; Charles R Flynn; Patricia Ashby; Adam Hansen; Daphne P Ly; George P Yang; Michael T Longaker; Alyssa Panitch; Colleen M Brophy
Journal:  J Invest Dermatol       Date:  2008-09-11       Impact factor: 8.551

10.  CCN3 (NOV) is a negative regulator of CCN2 (CTGF) and a novel endogenous inhibitor of the fibrotic pathway in an in vitro model of renal disease.

Authors:  Bruce L Riser; Feridoon Najmabadi; Bernard Perbal; Darryl R Peterson; Jo Ann Rambow; Melisa L Riser; Ernest Sukowski; Herman Yeger; Sarah C Riser
Journal:  Am J Pathol       Date:  2009-04-09       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.